Following widespread vaccination and natural infection, much

of the human population has partial immunity to SARS‑CoV‑2.

A new variant arises that is less effectively neutralised by existing

antibodies, while retaining strong ACE2 binding and efficient transmission. The

variant shows no increased virulence or replication cost.

If introduced into such a population, what outcome is most

likely over time?